CTXR: Citius Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CTXR: Citius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 116.55
Enterprise Value ($M) 96.81
Book Value ($M) 85.33
Book Value / Share 0.54
Price / Book 1.37
NCAV ($M) -12.07
NCAV / Share -0.08
Price / NCAV -9.66

Profitability (mra)
Return on Invested Capital (ROIC) -0.45
Return on Assets (ROA) -0.37
Return on Equity (ROE) -0.42

Liquidity (mrq)
Quick Ratio 0.00
Current Ratio 5.06

Balance Sheet (mrq) ($M)
Current Assets 28.21
Assets 97.40
Liabilities 12.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -36.73
Net Income -32.54
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -29.06
Cash from Investing 0.00
Cash from Financing 13.83

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-31 13G BlackRock Inc. 5.30 260.32

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-12-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECT
2023-08-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECT
2023-05-12 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 1,258,614 274,583 458.37
2024-04-25 181,530 122,011 148.78
2024-04-24 281,723 118,001 238.75
2024-04-23 191,298 134,877 141.83

(click for more detail)

Similar Companies
CRIS – Curis, Inc. CRVO – CervoMed Inc.
CSBR – Champions Oncology, Inc. CUE – Cue Biopharma, Inc.
CVKD – Cadrenal Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io